Latest News for: her2
Edit
Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression free survival vs. THP as 1st line therapy for patients with HER2 positive metastatic breast cancer (AstraZeneca plc)
Public Technologies 21 Apr 2025
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in ...
Edit
Victoria Advocate
17 Apr 2025
Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
Victoria Advocate
17 Apr 2025
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied ....
Edit
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs ...
Business Wire 10 Apr 2025
Edit
Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that has spread or cannot be removed by surgery (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 09 Apr 2025
Edit
DATROWAY� Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative ...
Business Wire 08 Apr 2025
Edit
The Milton Standard Journal
07 Apr 2025
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
The Milton Standard Journal
07 Apr 2025
Edit
ENHERTU� Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, ...
Business Wire 04 Apr 2025
Edit
Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy (Form 6-K) (AstraZeneca plc)
Public Technologies 04 Apr 2025
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in ...
Edit
Enid News & Eagle
31 Mar 2025
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced ...
Enid News & Eagle
31 Mar 2025
Edit
The Galveston Daily News
31 Mar 2025
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
The Galveston Daily News
31 Mar 2025
- 1